CG Oncology
Irvine
About CG Oncology
CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: Less than $1M
- Total funding: $555.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2024)
- Ticker: nasdaq:CGON
- Website: cgoncology.com
- Phone: 949-200-7680
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Oncology
Social Profiles
Canonical: https://fsome.com/organization/cg-oncology-114649 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.